Forte Biosciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $23.3 million for the three months ended June 30, 2026, compared to a loss of $11.2 million for the same period in 2025. For the six months ended June 30, 2026, the net loss increased to $45.5 million from $26.9 million in the prior year. Operating expenses surged to $24.6 million for the second quarter of 2026, up from $11.6 million in the same quarter of 2025, primarily driven by increased research and development costs associated with its lead product candidate, FB102.
The company’s total assets rose significantly to $205.7 million as of June 30, 2026, compared to $82.8 million at the end of 2025. This increase was largely due to the successful public offering completed in April 2026, which generated gross proceeds of $172.5 million. Forte's cash and cash equivalents decreased to $49.6 million from $77.0 million at the end of 2025, reflecting cash used in operations and investments in U.S. Treasury bills. The company’s accumulated deficit also widened to $268.8 million as of June 30, 2026.
In terms of operational developments, Forte is advancing its clinical trials for FB102, which targets autoimmune diseases. The company recently announced positive topline data from its Phase 1b trial for vitiligo and is currently conducting a Phase 2 trial for celiac disease, with topline results expected in the second half of 2026. The company has also initiated a Phase 1b trial for alopecia areata. As of June 30, 2026, Forte had approximately 198.5 million in cash, cash equivalents, and short-term investments, which management believes will be sufficient to fund operations for at least the next twelve months.
Forte's strategic direction includes a merger agreement with argenx BV, announced on July 26, 2026, which involves a tender offer for all outstanding shares of the company at $77.00 per share. This acquisition is subject to customary closing conditions and reflects a significant strategic move for both companies. The merger is expected to enhance Forte's capabilities in developing its product candidates and expanding its market reach. The company continues to monitor macroeconomic conditions that may impact its operations, including geopolitical tensions and economic uncertainties, which could affect its future funding and operational plans.
About Forte Biosciences, Inc.
Forte Biosciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies targeting autoimmune diseases. Its lead candidate, FB102, is a monoclonal antibody aimed at conditions like celiac disease, vitiligo, alopecia areata, and type 1 diabetes. The company focuses on innovative biologics, regulatory approval processes, and strategic partnerships to address unmet medical needs in autoimmune markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov